Cinacalcet for hypercalcemia of parathyroid carcinoma
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.
| Composantes | DRUG-CINACALCET |
|---|
| ID | REG-CINACALCET-HYPERCALCEMIA |
|---|---|
| Type | Protocole thérapeutique |
| État | reviewed 2026-07-11 | pending_clinical_signoff |
| Maladies | Aucune déclaration |
| Sources | SRC-NCCN-THYROID-2025 |
Notes
STUB pending clinical co-lead signoff (CHARTER §6.1 — dev-mode- exempted draft content). Cinacalcet controls PTH-driven hypercalcemia in unresectable, recurrent, or metastatic parathyroid carcinoma; it has no direct antitumor effect. Re-resection of accessible disease, where surgically feasible, remains the preferred disease-directed intervention alongside this regimen in the recurrent/metastatic setting (see IND-PARATHYROID-CARCINOMA-2L-CINACALCET) — not encoded as a regimen component because surgical feasibility is patient/anatomy-specific, not a fixed pharmacologic step. Bisphosphonates (DRUG-ZOLEDRONATE) or denosumab (DRUG-DENOSUMAB) are complementary options for skeletal-related-event prevention in bone-metastatic disease and for hypercalcemia refractory to cinacalcet alone — not bundled into this regimen because they act on a distinct mechanism (osteoclast-mediated bone turnover vs. PTH secretion) and no fixed combination schedule is established in guidelines; use per concurrent clinical need alongside this regimen.
Utilisé par
Maladie
DIS-PARATHYROID-CARCINOMA- Carcinome parathyroïdien
Indication
IND-PARATHYROID-CARCINOMA-2L-CINACALCET- IND-PARATHYROID-CARCINOMA-2L-CINACALCET